Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol for Treatment Resistant Depression
NCT03923361Phase 3Withdrawn
- Sponsor
- University of Utah
- Start
- Apr 2019
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of propofol injection (veterinary) in major depressive disorder (MDD) and bipolar disorder (BD), sponsored by University of Utah. Primary endpoint: Hamilton Rating Scale for Depression at 3 weeks. Planned start Apr 2019; status: withdrawn.
02
Drugs
propofol injection (veterinary)
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT03923361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03923361.